The Effect of Aspirin on Moderate to Severe Asthmatic Patients With Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis Publisher Pubmed



Arshi S¹ ; Darougar S² ; Nabavi M¹ ; Bemanian MH¹ ; Fallahpour M¹ ; Shokri S¹ ; Ahmadian J³ ; Molatefi R⁴ ; Rekabi M⁵ ; Moinfar Z⁶ ; Hashemitari P⁷ ; Eslami N⁸ Show Affiliations
Source: Iranian Journal of Allergy# Asthma and Immunology Published:2021

Abstract

Asthmatic patients may have aspirin-exacerbated respiratory disease and experience acute dyspnea and nasal symptoms within 3 hours after the ingestion of aspirin. This study aimed to evaluate the effect and outcome of daily low-dose aspirin in the treatment of moderate to severe asthma in patients with concomitant aspirin hypersensitivity and chronic rhinosinusitis with nasal polyposis (CRSwNP). This clinical trial was conducted from February 2014 to February 2015 on 46 adult patients with moderate to severe asthma accompanied by CRSwNP. Patients with a positive aspirin challenge were blindly randomized in three groups receiving placebo/day (A); aspirin 100 mg/day (B); and aspirin 325mg/day (C), respectively. Clinical findings, FEV1 and ACT scores were recorded and compared before, during, and after treatment for 6 months (IRCT2015061521970N2). Of 46 participants at baseline, 30 patients completed this 6-month trial study. The level of asthma control was significant; based on Asthma Control Test (ACT) when comparing the results in groups A and C and also groups B and C, but it was not significant when comparing ACT scores between groups A and B. FEV1 before and after treatment was significant when comparing groups A and B, groups A and C, and groups B and C. To conclude, aspirin desensitization with a daily dose of 325 mg aspirin resulted in the improvement of long-term control of asthma. A daily aspirin dose of 100 mg was not associated with such an increase in ACT score. Copyright © 2021 Arshi et al.